CollPlant Biotechnologies (CLGN), a regenerative and aesthetics medicine company, reported Thursday that its fiscal 2023 net loss narrowed to $7.0 million or $0.62 basic loss per share from last year's net loss of $16.9 million or $1.53 basic loss per share.
Adjusted net loss for the year was $5.2 million, or $0.46 basic loss per share, compared to $15.2 million loss, or $1.37 basic loss per share a year ago.
Revenues were $11.0 million, including revenues mainly from AbbVie, CollPlant's business partner, compared to $299,000 for the year 2022. The increase was mainly related to the achievement of a milestone under the AbbVie Agreement, which triggered a $10.0 million payment and a $600,000 increase in sales of rhCollagen products.
Gross profit for the year was $9.0 million, compared to gross loss of $101,000 in 2022.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.